BioSpace12d
Lilly Cuts Mid-stage Relaxin Study in Chronic Kidney Disease for ‘Lack of Foreseeable Clinical Benefit’
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Nature18d
Relaxin-3 and Nucleus Incertus in Neurobiology
Moreover, the relaxin-3 receptor (RXFP3) has been implicated in aging-related diseases. Research indicates that RXFP3 can regulate DNA damage response and repair processes, which are critical as ...
Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...
Business Insider12d
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
About TX45, a long-acting Fc-relaxin fusion protein TX45 is an Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the G-protein ...
Tectonic shares tumble after rival drug trial termination
Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE:LLY) for chronic ...